Zai Lab reports Q4 EPS (80c), consensus (63c)

Reports Q4 revenue $109.1M, consensus $110.15M. “2024 was a defining year for Zai Lab (ZLAB), marked by strong sales growth, financial strength, and significant pipeline progress. As we look ahead, 2025 is set to be a transformative year with VYVGART’s continued momentum, three new product launches, progress with ZL-1310, and potential regulatory milestones for key assets,” said Dr. Samantha Du, Founder, Chairperson, and Chief Executive Officer of Zai Lab. “The VYVGART franchise generated $93.6 million in net product revenue in its exceptional first full year of launch, highlighting the strong demand for innovative therapies in China. With the recent acceptance of KarXT’s New Drug Application by China’s National Medical Products Administration in January, we are one step closer to bringing this novel medicine to patients in need in China. Meanwhile, our global asset, ZL-1310, demonstrated strong safety and efficacy data, reinforcing its potential as a first- and best-in-class DLL3 antibody-drug conjugate for the treatment of small cell lung cancer. Zai Lab is stronger than ever, with the infrastructure, innovation, and execution needed to bring medicines to patients around the world and create value for our shareholders.”